New data show AAV-delivered antibody fragments targeting oxidized phosphatidylcholines (PC-OxPL), a species of oxidized phospholipids, thereby neutralizing ...

Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- ...

New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism ...

SOUTH SAN FRANCISCO, CA, USA I May 6, 2025 I IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and ...

INGELHEIM, Germany I May 6, 2025 I Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the ...

I Frontera Therapeutics announced today that its proprietary recombinant adeno-associated virus (rAAV) gene therapy, FT-003 Injection, has ...

SAN DIEGO, CA, USA I May 5, 2025 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development ...

SUZHOU, China I May 5, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, ...

SHANGHAI, China I May 4, 2025 I On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its ...

PLAINSBORO, NJ, USA I May 2, 2025 I Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, ...

CAMBRIDGE, MA, USA I May 01, 2025 I Kronos Bio, Inc. (“Kronos Bio”) (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases ...